KOD vs. CADL, CGEN, GNFT, VCXB, INMB, CRDF, SCLX, ABOS, IPHA, and OPT
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Candel Therapeutics (CADL), Compugen (CGEN), Genfit (GNFT), 10X Capital Venture Acquisition Corp. III (VCXB), INmune Bio (INMB), Cardiff Oncology (CRDF), Scilex (SCLX), Acumen Pharmaceuticals (ABOS), Innate Pharma (IPHA), and Opthea (OPT). These companies are all part of the "biological products, except diagnostic" industry.
Kodiak Sciences (NASDAQ:KOD) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.
Kodiak Sciences' return on equity of -80.20% beat Candel Therapeutics' return on equity.
Kodiak Sciences currently has a consensus target price of $5.50, suggesting a potential upside of 72.68%. Candel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 71.07%. Given Kodiak Sciences' higher probable upside, research analysts plainly believe Kodiak Sciences is more favorable than Candel Therapeutics.
Kodiak Sciences has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
In the previous week, Kodiak Sciences and Kodiak Sciences both had 1 articles in the media. Kodiak Sciences' average media sentiment score of 0.00 equaled Candel Therapeutics'average media sentiment score.
Kodiak Sciences received 10 more outperform votes than Candel Therapeutics when rated by MarketBeat users. However, 50.00% of users gave Candel Therapeutics an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 45.4% of Kodiak Sciences shares are held by insiders. Comparatively, 44.6% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Candel Therapeutics has higher revenue and earnings than Kodiak Sciences. Candel Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Kodiak Sciences beats Candel Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
